Loading.
Preparing your Shotlee experience
Authenticating
Loading health data
Syncing preferences
Pharmaceuticals
Novo Nordisk Reduces Wegovy Price Up to 37% in India Amid Mounjaro Competition
S
Shotlee
Health & Wellness Team
2 min read
Preparing your Shotlee experience
Novo Nordisk has reduced the price of Wegovy in India by as much as 37% to better compete with Eli Lilly's Mounjaro. This decision follows Mounjaro's rise to become the best-selling weight-loss medication in India by value.
Novo Nordisk has implemented a price reduction for Wegovy in India, with the highest dose (2.4 mg) now priced at ₹16,400 monthly, a decrease from the previous ₹24,389.06. A document sent to distributors by Novo Nordisk India confirms this change. The lowest dose (0.25 mg) will now be sold at ₹10,850 per month, down from ₹16,260.94.
The price cut factors in the impact of GST 2.0.
Vikrant Shrotriya, managing director at Novo Nordisk India, stated that the company listened to both patient and doctor communities and took proactive steps for the benefit of the public.
These weight-loss medications, including Wegovy and Mounjaro, belong to the class of GLP-1 receptor agonists. These treatments promote a prolonged feeling of fullness and are prescribed for both obesity and diabetes. The price reduction occurred shortly after Mounjaro became the top-selling weight-loss drug in India by value in October.
According to Vishal Manchanda, an analyst at Systematix Institutional Equities, this price adjustment could be a preemptive move as generics are anticipated to enter the market in 2026. A reduced price point could help Novo Nordisk maintain competitiveness, especially considering Mounjaro's current success in India. Health tracking apps like Shotlee can help monitor the effectiveness of these drugs.
The active pharmaceutical ingredient in Wegovy, semaglutide, will lose its patent protection in India in March 2026. This opens the door for generic drug manufacturers to enter the market.
Reflecting the market's significance, both Novo Nordisk and Eli Lilly have partnered with local pharmaceutical companies, Emcure Pharmaceuticals Ltd. and Cipla Ltd., respectively. This collaboration aims to market Wegovy and Mounjaro under local brand names while maintaining the same cost. Experts suggest that this strategy will broaden the distribution of these weight-loss drugs throughout India.
⚠️ Disclaimer: This article is for informational purposes only. Consult your healthcare provider before starting any medication or supplement.
Original content from Hindustan Times
View Original Article
The global Peptide Therapeutics Market is experiencing substantial growth, projected to reach USD 82.19 billion by 2032. This expansion is fueled by the increasing need for specialized medications, particularly in oncology and metabolic diseases. The U.S. market is expected to reach USD 35.71 billion by 2032.
Dr. Reddy's Laboratories (DRL) is banking on semaglutide for future revenue, but faces challenges in securing timely approvals. The company aims to launch the drug domestically after patent expiration, while also navigating international regulatory hurdles.
An Indian court has granted Dr. Reddy's Laboratories Ltd permission to manufacture and export generic versions of Novo Nordisk's diabetes and obesity medications. This decision comes before the global patent expirations in 2026. The ruling allows export to countries without patent protection.
Monitor GLP-1 medications, peptide therapy, weight loss, and wellness metrics with our comprehensive health tracking app. Join thousands of users taking control of their health!
Start Tracking Free Forever! ✨